Rovin Capital UT ADV Purchases 339 Shares of Agilent Technologies, Inc. $A

Rovin Capital UT ADV lifted its holdings in Agilent Technologies, Inc. (NYSE:A) by 8.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,500 shares of the medical research company’s stock after purchasing an additional 339 shares during the quarter. Rovin Capital UT ADV’s holdings in Agilent Technologies were worth $531,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Verdence Capital Advisors LLC boosted its stake in shares of Agilent Technologies by 5.0% during the 2nd quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock worth $215,000 after purchasing an additional 86 shares during the period. Burney Co. increased its stake in Agilent Technologies by 4.8% in the 2nd quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock worth $231,000 after buying an additional 90 shares during the period. Valeo Financial Advisors LLC increased its stake in Agilent Technologies by 3.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock worth $403,000 after buying an additional 102 shares during the period. Cary Street Partners Financial LLC grew its stake in Agilent Technologies by 2.9% in the first quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company’s stock worth $431,000 after purchasing an additional 103 shares in the last quarter. Finally, Stratos Wealth Partners LTD. increased its holdings in Agilent Technologies by 0.3% during the 1st quarter. Stratos Wealth Partners LTD. now owns 41,334 shares of the medical research company’s stock worth $4,835,000 after purchasing an additional 124 shares during the period. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on A shares. UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and upped their target price for the stock from $130.00 to $170.00 in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their target price on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Rothschild & Co Redburn assumed coverage on shares of Agilent Technologies in a research report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 price objective on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company raised their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $149.62.

Agilent Technologies Stock Up 0.6%

Shares of A opened at $147.71 on Friday. The company has a market capitalization of $41.87 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84. The stock’s 50-day moving average price is $135.06 and its 200-day moving average price is $121.97. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the previous year, the company posted $1.32 earnings per share. Agilent Technologies’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, sell-side analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th were given a $0.248 dividend. The ex-dividend date was Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. Agilent Technologies’s payout ratio is 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.